Bristol-Myers Squibb Company NYQ · BMY
Price alert —
Sign in to get a one-time email the moment BMY crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · BMY
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11.5B | $2.7B | $3.4B | $0.8B | 23.3% | 29.3% |
| 2025-12-31 | $12.5B | $1.1B | $2.8B | $1.6B | 8.7% | 22.5% |
| 2025-09-30 | $12.2B | $2.2B | $3.6B | $6.0B | 18.0% | 29.8% |
| 2025-06-30 | $12.3B | $1.3B | $3.8B | $3.6B | 10.7% | 30.8% |
| 2025-03-31 | $11.2B | $2.5B | $3.5B | $1.7B | 21.9% | 31.2% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare BMY vs peers
Line BMY up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with BMY
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-04-30 | 1.58 | 1.42 | +11.2% | -3.9% |
| 2026-02-05 | 1.26 | 1.20 | +4.6% | +4.2% |
| 2025-10-30 | 1.63 | 1.52 | +7.5% | +1.0% |
| 2025-07-31 | 1.46 | 1.10 | +32.6% | +2.1% |
| 2025-04-24 | 1.80 | 1.50 | +19.9% | -1.6% |
| 2025-02-06 | 1.67 | 1.47 | +13.8% | -1.0% |
| 2024-10-31 | 1.80 | 1.50 | +20.0% | -2.6% |
| 2024-07-26 | 2.07 | 1.63 | +27.4% | -2.9% |
| 2024-04-25 | -4.40 | -4.40 | -0.1% | +0.3% |
| 2024-02-02 | 1.70 | 1.58 | +7.8% | -1.5% |
| 2023-10-26 | 2.00 | 1.77 | +13.0% | -3.7% |
| 2023-07-27 | 1.75 | 1.99 | -12.0% | +1.1% |
| 2023-04-27 | 2.05 | 1.97 | +3.9% | -1.2% |
| 2023-02-02 | 1.82 | 1.73 | +5.2% | +2.3% |
| 2022-10-25 | 1.99 | 1.83 | +8.5% | +2.3% |
| 2022-07-27 | 1.93 | 1.80 | +7.3% | -0.1% |
| 2022-04-29 | 1.96 | 1.90 | +3.3% | -0.2% |
| 2022-02-04 | 1.83 | 1.80 | +1.7% | +1.9% |
| 2021-10-27 | 2.00 | 1.92 | +4.3% | +1.1% |
| 2021-07-28 | 1.93 | 1.90 | +1.8% | -0.8% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| BMY ★ | $124B | 17.0 | 9.8 | 2.6 | 8.4 | 6.2 | 72.0% | 2.6% | 9.2% | 7.94% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 36.69%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 171,682,888 | 8.41% |
| Vanguard Capital Management LLC | 132,320,240 | 6.48% |
| State Street Corporation | 98,564,914 | 4.83% |
| JPMORGAN CHASE & CO | 92,475,194 | 4.53% |
| Charles Schwab Investment Management | 61,115,373 | 2.99% |
| Geode Capital Management, LLC | 55,286,174 | 2.71% |
| Vanguard Portfolio Management LLC | 46,230,155 | 2.26% |
| Bank of America Corporation | 32,586,981 | 1.60% |
| AQR Capital Management, LLC | 29,631,105 | 1.45% |
| Morgan Stanley | 29,198,554 | 1.43% |
Insider activity · 90d
5 buys / 0 sells · ratio 5.0 · Finnhub
- Samuels Theodore R. II BUY 70,361 @ $57.62
- McMullen Michael R. BUY 16,333 @ $57.62
- Rice Derica W BUY 41,069 @ $57.62
- Arduini Peter J BUY 72,816 @ $57.62
- YALE PHYLLIS R BUY 44,986 @ $57.62
- Haller Julia A M 0
- Haller Julia A M 34,079 @ $53.76
- Short Bartie Wendy M 8,040
- Short Bartie Wendy F 12,081 @ $54.72
- Short Bartie Wendy M 15,957
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-02 | FORM 4 | view · |
| 4 | 2026-07-02 | FORM 4 | view · |
| 4 | 2026-07-02 | FORM 4 | view · |
| 4 | 2026-07-02 | FORM 4 | view · |
| 4 | 2026-07-02 | FORM 4 | view · |
| 4 | 2026-06-16 | FORM 4 | view · |
| 4 | 2026-06-05 | FORM 4 | view · |
| 8-K | 2026-05-08 | CURRENT REPORT | view · |
| 4 | 2026-05-05 | FORM 4 | view · |
| 10-Q | 2026-04-30 | 10-Q | view · |
| 8-K | 2026-04-30 | 8-K | view · |
| 4 | 2026-04-02 | FORM 4 | view · |
| 4 | 2026-04-02 | FORM 4 | view · |
| 4 | 2026-04-02 | FORM 4 | view · |
| 4 | 2026-04-02 | FORM 4 | view · |
| 4 | 2026-04-02 | FORM 4 | view · |
| 4 | 2026-04-02 | FORM 4 | view · |
| 4 | 2026-04-02 | FORM 4 | view · |
| DEF 14A | 2026-03-25 | DEF 14A | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-12 | FORM 4 | view · |
| 4 | 2026-03-03 | FORM 4 | view · |
| 10-K | 2026-02-11 | 10-K | view · |
| 8-K | 2026-02-05 | 8-K | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 4 | 2026-02-03 | FORM 4 | view · |
| 8-K | 2026-01-12 | CURRENT REPORT | view · |
| 4 | 2026-01-05 | FORM 4 | view · |
| 4 | 2026-01-05 | FORM 4 | view · |
| 4 | 2026-01-05 | FORM 4 | view · |
| 4 | 2026-01-05 | FORM 4 | view · |
| 4 | 2026-01-05 | FORM 4 | view · |
| 8-K | 2025-11-18 | CURRENT REPORT | view · |
| 8-K | 2025-11-10 | FORM 8-K | view · |
| 4 | 2025-11-04 | FORM 4 | view · |
| 4 | 2025-11-04 | FORM 4 | view · |
| 4 | 2025-11-04 | FORM 4 | view · |
| 4 | 2025-11-04 | FORM 4 | view · |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment o…
Options picks · BMY
ITM + OTM ideas from the latest scanLoading…
Congress trades · BMY
STOCK Act disclosuresLoading…
SEC filings & insiders · BMY
EDGAR · liveLoading…
Holders · BMY
Institutions & insider activityLoading…